Tyra Biosciences is a clinical-stage biotech developing oral small molecule drugs targeting Fibroblast Growth Factor Receptor (FGFR) biology, focused on cancer and rare genetic conditions. Tyra has no approved products or revenue. Its lead candidate, dabogratinib, is an oral FGFR3-selective inhibitor in Phase 2 development across three indications: low-grade upper tract urothelial carcinoma (a rare kidney/ureter cancer), intermediate-risk non-muscle invasive bladder cancer, and achondroplasia, the most common form of dwarfism. Tyra's core argument is that existing FGFR inhibitors cause significant side effects — particularly from off-target inhibition of FGFR1 and FGFR2 — which limits effective dosing. Dabogratinib is designed to be more selective for FGFR3, which Tyra argues would allow more aggressive dosing with fewer side effects. Tyra's "3x3" strategy pursues three Phase 2 trials aimed at three potential pivotal studies, attempting to maximize the value of a single molecule across multiple indications. Beyond dabogratinib, Tyra has two earlier-stage Phase 1 programs: TYRA-430, an FGFR4/3 inhibitor for liver cancer, and TYRA-200, an FGFR inhibitor targeting bile duct cancer patients who have developed resistance to existing therapies. Tyra funds itself through equity raises, outsources manufacturing to contract manufacturers, and plans to commercialize independently in the U.S. if it reaches approval.